Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib with Radiotherapy for NSCLC with Brain Metastases
NCT03754530Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03754530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754530.